Tweet
OPKO Health, Inc came to my attention in Lucavia123's "insider buying" discussion. This company looks the next big thing. The company expects results of phase three study of Rayaldy - vitamin D supplement with market potential of billions. I am now searching information about phase 1 and 2 results. Additionally, the company CEO is purchasing shares consistently. What you guys think of this company?
-
-
No love for OPK?
-
chart looks like crap and financials are horrible....tell us what you know.Originally posted by Duniyo View PostNo love for OPK?=============================
I am HUGE! Bring me your finest meats and cheeses.
- $$$MR. MARKET$$$Comment
-
Speculative investing no need for charts or sound financial foundationsOriginally posted by mrmarket View Post
But seriously the company has pipeline of potential blockbuster drugs. However, I can't find their phase two trials to see their early results.
Comment
-
I always think of Peter Lynch in cases like this who would say whenever you hear the next AAA stock---go back to looking at the original AAA,or in this case instead of looking for the next JAZZ, relook at JAZZ itself
Comment
-
Bot JAZZ yesterday @ 152.70. Analysts' consensus PT $193.Originally posted by investorone View PostI always think of Peter Lynch in cases like this who would say whenever you hear the next AAA stock---go back to looking at the original AAA,or in this case instead of looking for the next JAZZ, relook at JAZZ itselfComment
-
Nice move Babe. Missed on that one. Did pick up some OPK tho'.Comment
-
-
After Lucavia123's "insider buying" discussion I did a little research and bought OPK at $7.96 on 1/27.
I do not think this is the next JAZZ at all, but did some research on Phil Frost, the CEO billionaire who directs one of his trusts to purchase OPK shares on almost a daily basis for over a year now.
My first concern was whether Frost was artificially propping up the share price, but the relatively small purchases led me to believe that was not the case; and I am hoping he simply is demonstrating his belief in the success that OPK will bring.
My purchase was based on my belief in Philip Frost and his history of making money in pharma. He got his start in pharma in the early 1970s when he took over Key Pharmaceuticals with billionaire partner Michael Jaharis to develop generics and veterinary products. They sold the company to Schering-Plough in 1986. Frost then founded generic drugmaker Ivax and sold it to Teva Pharmaceutical Industries for $7.6 billion in 2005.
While there are a variety of molecular studies going on to battle many problematic diseases, the one item that I foresee driving near term revenue is the OPK 4score test. The 4Kscore™ is a convenient blood test that measures the serum levels of four different prostate-derived kallikrein proteins: total PSA, free PSA, intact PSA and hK2. Levels of these biomarkers are combined with a patient's age and digital rectal exam (DRE) status using a proprietary algorithm to calculate the probability of a finding of aggressive prostate cancer. After a recent announcement of positive testing results from an important study segment, Philip Frost stated "These results reinforce our belief that the 4Kscore™ test will be an important addition to the urologists' means of assessing a patient's risk for aggressive prostate cancer as well as an important new diagnostic product for OPKO,"
I have no idea what the revenue of such a test will bring, but it is a driver towards recent bullishness on OPK.
Totally speculative with a proven CEO billionaire continuing to put more skin in the game.
-Adam
Old Hippy & Mortgage ProComment
Comment